Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
06 March 2020 | Story Thabo Kessah | Photo Tsepo Moeketsi
Dr Ocaya
Dr Richard Ocaya’s research addresses the skills development and transfer millennium goal of many governments globally.

With the Fourth Industrial Revolution becoming a reality, Dr Richard Ocaya’s research is receptive to the fact that Africa and the world need to re-imagine their research. His research focuses on electronic instrumentation design for scientific measurements, computational physics on atomic nano-atomic structures, and semiconducting organic compounds materials built on silicon to realise Schottky devices.

Software developer 
“I develop most of the instrumentation that I apply in my research – both software and hardware,” said Dr Ocaya, a Physics Lecturer and Programme Director: Physics and Chemistry on the UFS Qwaqwa Campus.

“I am active in scientific computing through the computing cluster and software development, mathematical physics for material science modelling, and embedded instrumentation design using microprocessors. I also have deep interest in radio and data telemetry, in which I hold a South African patent issued in 2013. My present international collaborations are with like-minded researchers in similar fields in Saudi Arabia, Turkey, Japan, Egypt, South Korea, and the United States,” he added.

How does his research talk to the real world?
“The driving principle of all areas of my research has always been to deploy cutting-edge research to actual, real-world applications for the immediate betterment of Africans. The areas of my research align closely with the millennium goals of many governments globally, including the Republic of South Africa. These goals pertain to skills development and transfer that position us to better address the challenges of energy, water, and other priorities.”

Dr Ocaya is currently co-promoting a PhD student, having previously supervised one PhD, two MSc, and more than twenty honours students. He is a self-taught electronics and computer programmer, whose curiosity led him to question ‘the voices and music coming from a box; a radio’. “In my quest to satisfy my curiosity, I collected many discarded devices, took them apart, and tried so many circuits, only to have them fail because the theory was lacking. After thousands of failed projects and with me barely thirteen and in lower secondary school, my first ever project actually worked,” he said.

NRF-rating
He is the author of the book Introduction to Control Systems Analysis using Point Symmetries: An application of Lie Symmetries, which is available in all major bookstores such as Amazon, in both print and e-book format. He is a C3 NRF-rated researcher whose work makes a pioneering contribution to the new and growing field of phononics, an independent field of the now established photonics.

“This field will someday lead to improved energy-storage devices and faster processors due to more efficient heat removal from nanodevices,” he concludes.


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept